SOURCE: Gene Express, Inc.

January 07, 2008 09:00 ET

Gene Express Appoints Jonathan Rowe to Senior VP of Strategy and Clinical Innovation

TOLEDO, OH--(Marketwire - January 7, 2008) - Gene Express, Inc. today announced the appointment of Jonathan D. Rowe, PhD to Senior Vice President of Strategy and Clinical Innovation.

Gerald Vardzel, CEO of Gene Express, commented, "We are excited to have Jonathan join our team with over 10 years of developing, managing and supporting strategic initiatives in the fields of pharmaceutical sciences, clinical research, as well as pre- and post-marketing of drug candidates. His main responsibility is to provide strategic medical and business development input to the clinical and commercial development of Gene Express's products, and Jonathan's extensive experience perfectly complements this role."

Prior to joining Gene Express, Dr. Rowe held numerous integral positions at Pfizer Inc. dating back to 1998. Most recently, he served as Senior Director of Worldwide Pharmaceutical Sciences in Pfizer's Global R&D Group. In this role, Jonathan was accountable for aligning strategy, developing business metrics and delivering on process and performance improvements for the Pharmaceutical Sciences division. This division consists of over 2700 colleagues, and is responsible for bringing newly discovered molecules to clinical trials, and product enhancements to existing products and candidates. Dr. Rowe's previous positions at Pfizer Inc. included: Director of Intellectual Property Strategy Management where he was responsible for developing and leading intellectual property lifecycle initiatives to increase the value and productivity of product franchises from candidates to post-marketing; and as Clinical Director of the Cardiovascular Risk Factors Group, Dr. Rowe designed, developed and managed phase IIIB and IV clinical studies, and lead the strategic medical input into the marketing and commercial development of Lipitor®.

Prior to joining Pfizer Inc., Dr. Rowe was a scientific advisor for the law firm of Kaye, Scholer where he provided scientific support for IP litigation in the biotechnology and pharmaceutical industry.

Dr. Rowe's PhD is from the Department of Biochemistry at the Albert Einstein College of Medicine (AECOM), where he researched the expression of genes and their associated proteins involved in drug detoxification. Dr. Rowe has an MS with a focus on molecular biology (AECOM) and an MA in reproductive endocrinology from the State University of New York at Binghamton. Dr. Rowe has published a number of articles in peer-reviewed journals, has served as a consultant on the topics of Innovation and Strategy Implementation, and currently serves as an expert panel member for The Innovator, a publication supported by and the Monitor Group's Innovation Practice.

Dr. Rowe stated, "I have been advocating the need for tailored or personalized medicine for years. The value of medicine greatly increases when a medical professional can confidently answer the questions; what class of drug, at what starting dose, for how long, is the best option to treat my unique patient? Gene Express is positioned to deliver on this goal, and I am honored to be part of this great leadership team."

About Gene Express, Inc.

Gene Express, Inc. accelerates and enables drug and molecular diagnostic development by providing standardized genomic data. The Company's proprietary and patented StaRT-PCR™ (Standardized Reverse Transcription Polymerase Chain Reaction) platform technology for measuring gene expression levels in cells, clinical biopsies and blood is being used by numerous pharmaceutical concerns, as well as leading academic centers. The Company's $3 billion focus market for licensing and contract services includes the drug development, academic and molecular diagnostics segments. Additional information is available on the Company's website at

Any forecasts, plans, projections and other information contained in this press release describing events or results that may occur in the future are "forward-looking statements" as defined in the United States Private Securities litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and important factors that are beyond the control of the Company that could cause actual results and events to differ materially from the results presently anticipated or projected. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to this cautionary statement. All forward-looking statements contained herein speak only as of the date of this release and are based on current expectations. The Company disclaims any obligation to update or revise any forward-looking statements.

Contact Information